```html

Rubella Congenital Syndrome (Congenital Rubella Syndrome)

Overview

Rubella congenital syndrome, more commonly called Congenital Rubella Syndrome (CRS), is a collection of birth defects that occur in infants whose mothers were infected with rubella (German measles) during pregnancy, especially in the first trimester. The rubella virus can cross the placenta and interfere with the normal development of organs and systems.

Who it affects: Any infant born to a mother infected with rubella while pregnant is at risk. The risk is highest when maternal infection occurs before 12 weeks gestation (≈ 90 % chance of fetal infection) and declines sharply thereafter.

Prevalence: In countries with robust vaccination programs, CRS is now rare (≈ 0.1–0.5 cases per 10,000 live births). In regions where the measles‑rubella vaccine coverage is <80 %, the World Health Organization (WHO) estimates 100,000–120,000 CRS cases worldwide each year [WHO, 2023]. In the United States, the CDC reports fewer than 5 cases per year since the introduction of the MMR vaccine in 1971 [CDC, 2022].

Symptoms

CRS is a multisystem disorder. Not every child will have all manifestations, but the classic triad includes:

• Sensorineural hearing loss – present in 50‑70 % of cases; often bilateral and moderate‑to‑severe.
• Eye abnormalities – cataracts, glaucoma, retinopathy, or microphthalmia.
• Congenital heart disease – most commonly patent ductus arteriosus (PDA) and pulmonary artery stenosis.

Other common findings

• Growth restriction – low birth weight and failure to thrive.
• Neurologic deficits – developmental delay, intellectual disability, spasticity, or seizures.
• Hepatosplenomegaly – enlarged liver and spleen, sometimes with jaundice.
• Thrombocytopenic purpura – low platelet count leading to bruising or petechiae.
• Skin rash – a transient maculopapular rash similar to that seen in acute rubella.
• Midline defects – cleft palate, micrognathia, or nasal cartilage abnormalities.

Causes and Risk Factors

CRS is caused by intrauterine infection with the rubella virus. The virus is an RNA togavirus transmitted primarily through respiratory droplets.

Primary cause

• Maternal rubella infection during pregnancy, most often before the 12th week.

Risk factors for the mother

• Living in or traveling to areas with low vaccination coverage.
• Absence of documented two‑dose measles‑mumps‑rubella (MMR) vaccination.
• Occupational exposure (e.g., health‑care workers, teachers) without immunity.
• Pregnancy during a rubella outbreak.

Why the first trimester is highest risk

During early organogenesis, the virus can disrupt cellular differentiation and induce apoptosis, leading to structural malformations. After 20 weeks, the fetal immune system is more capable of limiting viral spread, so later infections often cause milder or subclinical disease.

Diagnosis

Diagnosing CRS involves a combination of clinical observation, laboratory testing, and imaging.

1. Clinical criteria

• Presence of any two major defects (e.g., PDA + cataract) **or** one major defect plus laboratory evidence of rubella infection.

2. Laboratory tests

• Rubella-specific IgM antibodies in the infant’s serum – indicates recent infection (positive in ~70 % of CRS infants).
• Rubella-specific IgG antibodies persisting beyond 12 months of age – maternal IgG normally wanes by 6‑9 months; persistence suggests congenital infection.
• Polymerase chain reaction (PCR) on urine, throat swab, or cerebrospinal fluid (CSF) – detects viral RNA.

3. Imaging and functional studies

• Echocardiogram – evaluates PDA, pulmonary artery stenosis, septal defects.
• Ophthalmologic exam – slit‑lamp exam for cataract, retinal lesions.
• Audiology testing – brainstem evoked response audiometry (BERA) or otoacoustic emissions (OAE) to detect hearing loss.
• MRI of brain – when neurologic signs are present.

4. Differential diagnosis

Conditions that can mimic CRS include cytomegalovirus (CMV) infection, toxoplasmosis, syphilis, and genetic syndromes (e.g., trisomy 13). Comprehensive TORCH screening may be ordered to rule these out.

Treatment Options

There is no cure for the viral infection itself once the child is born, but many of the complications are treatable or manageable.

Medical interventions

• Cardiac surgery or catheter‑based interventions – closure of PDA, repair of pulmonary artery stenosis, or valve replacement when indicated.
• Cataract extraction – performed usually before 6 months of age to prevent amblyopia.
• Antiviral therapy – not routinely recommended; ribavirin has been studied but lacks safety data in neonates.
• Hematologic support – platelet transfusions for severe thrombocytopenia.

Therapies for functional deficits

• Hearing rehabilitation – hearing aids, cochlear implants, and early speech‑language therapy.
• Early intervention programs – physical, occupational, and developmental therapy to address motor and cognitive delays.
• Vision therapy – corrective lenses, amblyopia patching, and regular ophthalmology follow‑up.

Lifestyle & supportive care

• Nutrition optimization – high‑calorie formula or breast‑milk supplementation for failure to thrive.
• Immunizations – ensure routine vaccines (except live rubella) are administered on schedule; children with CRS can receive all standard vaccines because they are not infected with live virus.
• Family counseling – psychosocial support and genetic counseling for future pregnancies.

Living with Rubella Congenital Syndrome

While CRS presents lifelong challenges, many children lead productive lives with appropriate support.

Daily management tips

• Routine hearing checks – at least annually, or sooner if speech delays appear.
• Vision monitoring – regular eye exams, especially after cataract surgery.
• Cardiac follow‑up – echocardiograms at birth, before school age, and whenever symptoms (e.g., fatigue, poor growth) develop.
• Growth tracking – chart weight, height, and head circumference; involve a pediatric nutritionist if growth falters.
• Early education services – enroll in preschool programs that provide speech, occupational, and physical therapy.
• Vaccination vigilance – keep an up‑to‑date immunization record; avoid exposure to rubella‑infected individuals.
• Home safety – use hearing‑aid battery safety precautions and ensure adequate lighting for visual impairments.

Psychosocial considerations

Parents may experience guilt or anxiety. Connecting with support groups (e.g., the National Rubella Foundation) and mental‑health professionals can improve coping.

Prevention

The single most effective strategy is **vaccination**.

• MMR vaccine – two doses (first at 12‑15 months, second at 4‑6 years) provide >97 % immunity. Women of child‑bearing age should have documented immunity before pregnancy.
• Pre‑conception screening – check rubella IgG titers; vaccinate non‑immune women at least one month before conception.
• Outbreak control – rapid identification of rubella cases, isolation, and post‑exposure prophylaxis (immune globulin) for pregnant contacts.
• Public health measures – maintaining >95 % vaccination coverage in the community to achieve herd immunity.

Complications

If left untreated or inadequately managed, CRS can lead to serious, sometimes life‑threatening complications:

• Severe, permanent hearing loss – impacts language development and education.
• Irreversible visual impairment – may lead to blindness.
• Congestive heart failure – due to large PDA or pulmonary artery stenosis.
• Neurodevelopmental disability – intellectual impairment, seizures, or autism spectrum features.
• Growth failure – chronic malnutrition and endocrine disturbances.
• Psychosocial impact – reduced quality of life, academic challenges, and increased caregiver burden.

When to Seek Emergency Care

References

• World Health Organization. Rubella and Congenital Rubella Syndrome – Global update 2023. WHO; 2023.
• Centers for Disease Control and Prevention. Congenital Rubella Syndrome (CRS) Fact Sheet. CDC; 2022.
• Mayo Clinic. Congenital rubella syndrome. Updated 2024.
• Cleveland Clinic. Rubella (German measles) and pregnancy. 2024.
• National Institute of Child Health & Human Development. Rubella and the developing fetus. NIH; 2023.

```